McBride linked thalidomide to birth defects — then fabricated data to repeat it

William McBride, an Australian obstetrician, published a letter in The Lancet in December 1961 linking the drug thalidomide to birth defects — one of the first published warnings about the drug's teratogenic effects. His observation was correct and contributed to the withdrawal of thalidomide, saving countless lives.

But McBride's later career was marred by research fraud. In the 1980s, he published studies on the effects of the drug Debendox (doxylamine) on birth defects. An investigation found that McBride had fabricated and manipulated data in these studies. He was struck from the medical register in 1988.

The case was a tragic paradox: a researcher who had made a genuine and important discovery destroyed his own credibility through fraud. McBride's thalidomide warning was valid and heroic; his later fabrication was inexcusable. The case illustrated how a scientist's early success does not immunize them against later misconduct, and how the pressure to replicate past glory can drive a researcher to fabricate.

McBride's correct 1961 thalidomide warning made his name, but he later fabricated data in a Debendox paper, was struck off in 1988, and reinstated in 1998.

McBride's 1961 thalidomide warning was correct and contributed to the drug's withdrawal.

His later studies on Debendox were based on fabricated and manipulated data.

He was struck from the medical register in 1988.

The case was a paradox: a genuine discovery overshadowed by later fraud.

The reputation that makes a finding credible is the same reputation nobody wants to check. McBride's fabrication was caught by the people whose names were on the paper, not by review.

McBride was struck from the medical register in 1988. His thalidomide warning remains a landmark in pharmacovigilance. The case is cited as an example of how research fraud can destroy a career built on genuine achievement.